5:45 PM
Jun 26, 2013
 |  BC Extra  |  Clinical News

Tolerion reports Phase II data for Type I diabetes vaccine

Tolerion Inc. (Portola Valley, Calif.) said all doses of once-weekly intramuscular TOL-3021 for 12 weeks improved C-peptide levels, a marker of pancreatic beta cell function, relative to placebo in a Phase II trial to treat Type I diabetes. TOL-3021 also significantly reduced the number of proinsulin-reactive...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >